Recommended

FDA tightens COVID vaccine use
Decentralised manufacturing consortium launched
Trial boost for myasthenia gravis drug
FDA starts publishing daily AE data
WEBINAR | The Future of Sterility Testing: One-Day Results with Advanced RT-rt PCR Technology | 5 NOV
WEBINAR | Mastering Impurity Profiling: USP’s Evolving Standards and Strategies | 15 OCT
news

Imbruvica® granted expanded use from European Commission

1
SHARES

The European Commission has approved the drug for two indications: chronic lymphocytic leukaemia and Waldenström’s macroglobulinemia.

The European Commission (EC) has approved Imbruvica® (ibrutinib) for expanded use in two in indications. The drug is a first-in-class Bruton’s tyrosine kinase (BTK) inhibitor and represents the fifth EC approval in five years.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The two variations include broadening the use of Imbruvica in combination with obinutuzumab in adult patients with previously unrelated chronic lymphocytic leukaemia (CLL) and the use of the drug with rituximab for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).

Janssen, a division of Johnson & Johnson, produce the medication and received a Positive Opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) in June.

“With five EC approvals in five years, this latest EC decision further extends the potential reach and impact ibrutinib can have for patients,” said Craig Tendler, Vice President, Clinical Development and Global Medical Affairs, Oncology, Janssen Research and Development, LLC. “We remain committed to a comprehensive clinical development programme for ibrutinib, including exploring its use in other combinations, to address the needs of more and more patients with B-cell malignancies.”

The medication works by forming a strong covalent bond with BTK to block the transmission of cell survival signals within the malignant B-cells. By blocking this BTK protein, ibrutinib decreases survival and migration of B lymphocytes, which delays the progression of cancer.

Share via
Share via